Call for Letters of Intent for studies that will improve outcomes for recurrent osteosarcoma patients

Translational studies

Briefly, an ideal dataset would have the following features:

• a drug target demonstrated to be relevant in osteosarcoma, rigorously and mechanistically tested in multiple preclinical models across preclinical model species, and in human osteosarcoma cells and/or lesions
• the availability of a therapeutic candidate or drug suitable for preclinical studies and future human translation; a testable PD marker of effective drug exposure
• a correlative biomarker that may be translated to human patients in support of optimal dosing

Funding: $250,000 per year 

Duration: 2 years

Research Authority due dates: 8.11.20

LOI  (required) due date: 15.11.20

Full proposal due date: 15.4.21